LeMaitre Vascular (LMAT) Stock Price, News & Analysis

+0.87 (+1.39%)
(As of 10:11 AM ET)
Today's Range
50-Day Range
52-Week Range
5,970 shs
Average Volume
111,948 shs
Market Capitalization
$1.43 billion
P/E Ratio
Dividend Yield
Price Target

LeMaitre Vascular MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
8.7% Upside
$68.20 Price Target
Short Interest
3.87% of Float Sold Short
Dividend Strength
Based on Four Factors
News Sentiment
0.19mentions of LeMaitre Vascular in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$7.87 M Sold Last Quarter
Proj. Earnings Growth
From $1.66 to $1.82 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.08 out of 5 stars

Medical Sector

309th out of 910 stocks

Surgical & Medical Instruments Industry

36th out of 97 stocks

LMAT stock logo

About LeMaitre Vascular Stock (NASDAQ:LMAT)

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

LMAT Stock Price History

LMAT Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
LeMaitre Vascular, Inc. (LMAT)
LeMaitre Vascular (NASDAQ:LMAT) Cut to "Hold" at
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
LMAT Mar 2024 70.000 put
LeMaitre Vascular, Inc.: LeMaitre Q4 2023 Financial Results
Q4 2023 LeMaitre Vascular Inc Earnings Call
Recap: LeMaitre Vascular Q4 Earnings
See More Headlines
Receive LMAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Ex-Dividend for 3/28 Dividend
Dividend Payable
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
$30.10 million
Pretax Margin


Sales & Book Value

Annual Sales
$193.48 million
Cash Flow
$1.77 per share
Book Value
$13.38 per share


Free Float
Market Cap
$1.41 billion

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

LMAT Stock Analysis - Frequently Asked Questions

Should I buy or sell LeMaitre Vascular stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LMAT shares.
View LMAT analyst ratings
or view top-rated stocks.

What is LeMaitre Vascular's stock price target for 2024?

6 Wall Street analysts have issued 1-year price objectives for LeMaitre Vascular's shares. Their LMAT share price targets range from $60.00 to $75.00. On average, they expect the company's share price to reach $68.20 in the next year. This suggests a possible upside of 8.7% from the stock's current price.
View analysts price targets for LMAT
or view top-rated stocks among Wall Street analysts.

How have LMAT shares performed in 2024?

LeMaitre Vascular's stock was trading at $56.76 at the start of the year. Since then, LMAT stock has increased by 10.6% and is now trading at $62.77.
View the best growth stocks for 2024 here

When is LeMaitre Vascular's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our LMAT earnings forecast

How can I listen to LeMaitre Vascular's earnings call?

LeMaitre Vascular will be holding an earnings conference call on Thursday, May 2nd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) released its quarterly earnings data on Tuesday, February, 27th. The medical instruments supplier reported $0.38 EPS for the quarter, beating analysts' consensus estimates of $0.36 by $0.02. The medical instruments supplier had revenue of $48.90 million for the quarter, compared to analyst estimates of $49.01 million. LeMaitre Vascular had a trailing twelve-month return on equity of 10.57% and a net margin of 15.56%. LeMaitre Vascular's quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter last year, the company posted $0.25 earnings per share.

How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?

LeMaitre Vascular declared a quarterly dividend on Wednesday, February 21st. Stockholders of record on Thursday, March 14th will be given a dividend of $0.16 per share on Thursday, March 28th. This represents a $0.64 annualized dividend and a yield of 1.02%. The ex-dividend date is Wednesday, March 13th. This is a boost from the stock's previous quarterly dividend of $0.14.
Read our dividend analysis for LMAT

Is LeMaitre Vascular a good dividend stock?

LeMaitre Vascular (NASDAQ:LMAT) pays an annual dividend of $0.64 per share and currently has a dividend yield of 1.01%. The company has been increasing its dividend for 13 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 47.76%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LMAT will have a dividend payout ratio of 35.16% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LMAT.

What guidance has LeMaitre Vascular issued on next quarter's earnings?

LeMaitre Vascular updated its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of 0.360-0.410 for the period, compared to the consensus estimate of 0.340. The company issued revenue guidance of $50.5 million-$52.9 million, compared to the consensus revenue estimate of $50.2 million.

What is George W. LeMaitre's approval rating as LeMaitre Vascular's CEO?

13 employees have rated LeMaitre Vascular Chief Executive Officer George W. LeMaitre on George W. LeMaitre has an approval rating of 33% among the company's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of LeMaitre Vascular own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Adobe (ADBE), Boeing (BA) and Salesforce (CRM).

Who are LeMaitre Vascular's major shareholders?

LeMaitre Vascular's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Congress Asset Management Co. MA (2.99%), Congress Wealth Management LLC DE (0.44%), Bridge City Capital LLC (0.33%), Chatham Capital Group Inc. (0.22%), Annex Advisory Services LLC (0.12%) and Los Angeles Capital Management LLC (0.10%). Insiders that own company stock include Bridget A Ross, David B Roberts, George W Lemaitre, George W Lemaitre, John A Roush, Joseph P Pellegrino Jr, Lawrence J Jasinski and Trent G Kamke.
View institutional ownership trends

How do I buy shares of LeMaitre Vascular?

Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does LeMaitre Vascular have any subsidiaries?
The following companies are subsidiares of LeMaitre Vascular: Artegraft, Bio Nova Holdings Pty Ltd, Bio Nova International Pty Ltd, Biomateriali, CardioCel, Clinical Instruments, Credent, Endomed, Ideas for Medicine, Inavein, LeMaitre Acquisition LLC, LeMaitre Cardial SAS, LeMaitre Medical Technology (Shanghai) Co., LeMaitre Vascular, LeMaitre Vascular AS, LeMaitre Vascular GK, LeMaitre Vascular GmbH, LeMaitre Vascular Pty Ltd, LeMaitre Vascular S.r.l., LeMaitre Vascular SAS, LeMaitre Vascular Singapore Pte Ltd, LeMaitre Vascular Spain, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LifeSpan, PeriVu, ProCol, Restore Flow Allografts, RestoreFlow, Syntel and Python, TRIVEX, Tru-Incise (Eze-Sit) OUS, Tru-Incise (Eze-Sit) US, UnBalloon, VCS Clip, VascuCel, Vascular Architects, Vascular Innovations, Vascutech Acquisition LLC, Vermed, Whittaker Screen Printing, XenoSure, and Xenotis Pty Ltd.
Read More
This page (NASDAQ:LMAT) was last updated on 4/23/2024 by Staff

From Our Partners